Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 6 Excess mortality with oral glycoprotein IIb/IIIa antagonists. All trials demonstrate a consistent increase in total mortality. p = 0.5888 Breslow-Day heterogeneity. CI = confidence interval; EXCITE = Evaluation of oral Xemilofiban In controlling Thrombotic Events trial; OPUS = Optimal angioplasty and primary stenting trial; SYMPHONY = Sibrafiban vs. aspirin to Yield Maximum Protection from ischemic Heart events pOst acute coroNary sYndromes. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001;103:201–6. Reproduced with permissions from Lippincott, Williams and Wilkins.
